ESMO 24: Replimune’s Cancer Vaccine Succeeds In PD-1 Failures
New data suggest that RP1 could become the therapy of choice in melanoma patients who do not respond to checkpoint inhibitors.
New data suggest that RP1 could become the therapy of choice in melanoma patients who do not respond to checkpoint inhibitors.